GlaxoSmithKline is investing $23.5 million in Kurma Biofund II, a venture capital fund that works with a network of research institutes in Europe and focuses on rare diseases. GSK invested earlier this year in Avalon Ventures to fund up to 10 drug discovery startup companies over the next three years.

Full Story:

Related Summaries